5,611 Shares in Biohaven Ltd. (NYSE:BHVN) Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. acquired a new stake in shares of Biohaven Ltd. (NYSE:BHVN) in the fourth quarter, HoldingsChannel reports. The fund acquired 5,611 shares of the company’s stock, valued at approximately $210,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Point72 Asset Management L.P. grew its position in shares of Biohaven by 745.9% during the third quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company’s stock worth $74,969,000 after buying an additional 1,322,922 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Biohaven by 563.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 508,622 shares of the company’s stock worth $25,416,000 after acquiring an additional 431,954 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Biohaven by 85.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company’s stock worth $40,448,000 after purchasing an additional 372,737 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Biohaven by 5.6% in the 3rd quarter. Janus Henderson Group PLC now owns 6,226,393 shares of the company’s stock valued at $311,142,000 after purchasing an additional 328,099 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in shares of Biohaven by 600.9% during the third quarter. Wellington Management Group LLP now owns 243,167 shares of the company’s stock worth $12,151,000 after purchasing an additional 208,472 shares during the last quarter. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on BHVN shares. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 price objective on shares of Biohaven in a report on Tuesday, March 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research report on Tuesday, December 17th. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on shares of Biohaven and gave the stock a “buy” rating in a report on Thursday, March 20th. JPMorgan Chase & Co. lowered their target price on shares of Biohaven from $72.00 to $68.00 and set an “overweight” rating for the company in a research note on Wednesday, March 5th. Finally, HC Wainwright restated a “buy” rating and issued a $54.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. Fourteen analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $62.77.

Biohaven Stock Down 2.8 %

Biohaven stock opened at $27.59 on Friday. The firm has a 50-day moving average price of $35.15 and a two-hundred day moving average price of $41.32. Biohaven Ltd. has a 52-week low of $26.57 and a 52-week high of $55.72. The firm has a market capitalization of $2.82 billion, a price-to-earnings ratio of -2.95 and a beta of 1.27.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.29). Research analysts expect that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director John W. Childs acquired 29,000 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average cost of $35.94 per share, for a total transaction of $1,042,260.00. Following the completion of the purchase, the director now directly owns 2,368,741 shares in the company, valued at $85,132,551.54. This trade represents a 1.24 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 16.00% of the stock is currently owned by insiders.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.